{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049073","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.013840+00:00","generated_at":"2026-06-10T10:34:41.516982+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HeartSciences signs definitive license agreements with Icahn Mount Sinai for AI ECG algorithms and data access","bullets":["Entered into 11 license agreements for 13 algorithms, 2 data science methods, and 3 patent filings related to AI ECG analysis.","Mount Sinai will receive 15% of HeartSciences' common stock upon closing of a $5M financing, plus warrants for 914,148 shares at $0.5060.","Royalties: low-single digit percentages of annual net sales of licensed products; sublicense revenue share also required.","Also signed MOU for de-identified data access, ongoing research, and evaluation of HeartSciences' MyoVista wavECG device.","HeartSciences plans to develop a cloud-based, device-agnostic platform to deploy algorithms broadly."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049073","json":"https://secwatch.observer/filing/0000950170-23-049073.json","markdown":"https://secwatch.observer/filing/0000950170-23-049073.md","text":"https://secwatch.observer/filing/0000950170-23-049073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/0000950170-23-049073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/hscs-20230920.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:34:41.516982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bf690225cd8cf0c01c059e64d5e524b6afc4523","claim":"HeartSciences Inc. entered into License Agreements with Icahn School of Medicine at Mount Sinai (effective 2023-09-20).","evidence_excerpt":"On September 20, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into several definitive license agreements (each a “License Agreement” and collectively, the “License Agreements”) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/0000950170-23-049073-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Icahn School of Medicine at Mount Sinai"},{"label":"Effective","value":"2023-09-20"}],"fact_type":"material_agreement"},{"claim_id":"68983a7fbdc7a00584402ba47c2e5cdf4b29c8ab","claim":"HeartSciences Inc. entered into Securities Purchase Agreement with Icahn School of Medicine at Mount Sinai (effective 2023-09-20).","evidence_excerpt":"on September 20, 2023, the Company and Mount Sinai entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement”), pursuant to which the Company agreed to sell to Mount Sinai as of the Closing Date (as defined below)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023049073/0000950170-23-049073-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Icahn School of Medicine at Mount Sinai"},{"label":"Effective","value":"2023-09-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}